**Table e-1. Comparisons of serum biomarker levels according to clinical status**

|  |  |  |  |
| --- | --- | --- | --- |
|  | MOGAD | NMOSD | p-valuea |
| Total, median (IQR), pg/mL |
| NfL (n=16, 31) | 10.7 (7.7–17.5) | 15.2 (12.1–24.8) | 0.363 |
| GFAP (n=16, 26) | 90.2 (59.9–116.1) | 123.1 (95.3–234.1) | 0.020 |
| Tau (n=15, 31) | 0.4 (0.2–0.5) | 0.5 (0.4–0.8) | 0.066 |
| Relapse states, median (IQR), pg/mL |
| NfL (n=7, 11) | 10.2 (7.4–22.9) | 34.8 (12.2–62.3) | 0.324 |
| GFAP (n=7, 8) | 102.5 (87.1–142.0) | 253.8 (150.6–303.0) | 0.057 |
| Tau (n=7, 11) | 0.5 (0.4–0.5) | 0.5 (0.1–1.0) | 0.534 |
| Remission states, median (IQR), pg/mL  |
| NfL (n=9, 20) | 10.9 (7.7–16.3) | 13.0 (11.3–20.0) | 0.365 |
| GFAP (n=9, 18) | 68.4 (58.9–115.0) | 104.4 (93.9–127.9) | 0.034 |
| Tau (n=8, 20) | 0.2 (0.1–0.3) | 0.5 (0.4–0.8) | 0.005 |

a Analysis of covariance (ANCOVA) was conducted for serum biomarker comparisons after age and EDSS adjustments.

**Table e-2. Correlation of serum biomarkers with age**

|  |  |  |
| --- | --- | --- |
|  | Not adjusted | Adjusted with sex and treatment |
|  | Pearson r | p-value | Pearson r | p-value |
| MOGAD |  |  |  |  |
| logNfL, (n=16) | 0.068 | 0.802 | 0.019 | 0.950 |
| logGFAP, (n=16) | −0.097 | 0.720 | −0.095 | 0.746 |
| logTau, (n=15) | −0.194 | 0.489 | −0.280 | 0.355 |
| NMOSD |  |  |  |  |
| logNfL, (n=31) | 0.504 | 0.004 | 0.483 | 0.007 |
| logGFAP, (n=26) | 0.251 | 0.217 | 0.109 | 0.606 |
| logTau, (n=31) | −0.192 | 0.300 | −0.179 | 0.345 |

**Table e-3. Correlation of serum biomarkers with EDSS**

|  |  |  |
| --- | --- | --- |
|  | Not adjusted | Adjusted with sex and treatment |
|  | Pearson r | p-value | Pearson r | p-value |
| MOGAD |  |  |  |  |
| logNfL, (n = 16)  | 0.684 | 0.003 | 0.694 | 0.006 |
| logGFAP, (n = 16) | 0.107 | 0.693 | 0.130 | 0.657 |
| logTau, (n = 15) | 0.524 | 0.045 | 0.583 | 0.037 |
| NMOSD |  |  |  |  |
| logNfL, (n = 31) | 0.220 | 0.234 | 0.237 | 0.207 |
| logGFAP, (n = 26) | 0.485 | 0.012 | 0.477 | 0.016 |
| logTau, (n=31) | 0.068 | 0.716 | 0.063 | 0.741 |

**Figure e-1. Flow chart of patient inclusion**